HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
herdoo2 score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–1
  • Not Low Risk2–4
Direct Clinical Answer

The HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include post thrombotic signs. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Identifies low-risk women who can safely discontinue anticoagulation after completing treatment for unprovoked venous thromboembolism (VTE). The rule helps clinicians decide which patients can stop anticoagulation therapy after the initial treatment period.

Clinical Indication

The HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE is indicated for bedside clinical practice to support Identifies low-risk women who can safely discontinue anticoagulation after completing treatment for unprovoked venous thromboembolism (VTE). The rule helps clinicians decide which patients can stop anticoagulation therapy after the initial treatment period.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Not applicable to men or women with provoked VTE.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

Score = Post-thrombotic signs (1 point) + D-dimer ≥250 μg/L (1 point) + BMI ≥30 kg/m² (1 point) + Age ≥65 years (1 point)

Input Parameters

NameTypeRequiredDescription
post_thrombotic_signsstringYesHyperpigmentation, edema, or redness in either leg
d_dimer_levelstringYesD-dimer level measured while on anticoagulation
bmistringYesBody Mass Index
agestringYesPatient age

Score Interpretation & Guidance

RangeStageDescription
0–1Low RiskCan discontinue anticoagulation
2–4Not Low RiskContinue anticoagulation

Evidence-Based References (EBM)

  • Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008 Aug 26;179(5):417-26.
  • Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, et al.; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017 Mar 17;356:j1065.

Related calculators